Telehealth company Hims & Hers on Monday announced a \u201cstrategic shift\u201d in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop selling the \u201ccopycat\u201d compounded versions it has long advertised.<\/p>\n
In a press release<\/a>, Hims & Hers said it will \u201cno longer advertise compounded GLP-1 offerings on its platform or in its marketing, and existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers.\u201d<\/p>\n \u201cWe see tremendous growth opportunities in the US with the expanding assortment of branded GLP-1 medications,\u201d said Andrew Dudum, co-founder and CEO of Hims & Hers.<\/p>\n \u201cI\u2019m excited to have a great partner in Novo Nordisk as we work to create a new model that works for everyday people. This collaboration reflects what\u2019s possible globally when drugmakers, biotech companies, and diagnostic leaders partner with consumer platforms to support scaled distribution of their latest medical innovations.\u201d<\/p>\n Hims & Hers will now offer Food and Drug Administration-approved semaglutide products, which include Novo Nordisk\u2019s Ozempic and Wegovy, on a \u201climited scale.\u201d This represents a drastic change for the online company, which has attributed the sale of compounded GLP-1s as a significant driver of its growth. The company even purchased a compounding pharmacy in 2024.<\/p>\n \u201cThis agreement with Hims & Hers is a meaningful win for patients in the United States. By expanding access through leading telehealth providers and digital care platforms, we are helping to connect more people with our FDA-approved medicines, which have been evaluated for safety and efficacy,\u201d Novo Nordisk President and CEO Mike Doustdar said in a statement<\/a>.<\/p>\n The collaboration between the two companies will offer both the injectable versions of semaglutide and the recently approved oral version of Wegovy.<\/p>\n This is not the first time the two companies have attempted to cooperate. When semaglutide came out of shortage, Novo partnered with several telehealth platforms to offer its GLP-1 products. The company ended its partnership<\/a> with Hims & Hers soon after because the telehealth platform continued to offer compounded versions of Ozempic and Wegovy.<\/p>\n Just last month, Novo Nordisk filed a<\/a> lawsuit<\/a> against Hims & Hers for selling what it alleged to be \u201cunapproved knock-off versions of Wegovy\u00ae and Ozempic\u00ae.\u201d<\/p>\n On Monday, attorneys for Novo Nordisk submitted a notice of voluntary dismissal regarding the lawsuit.<\/p>\n This shift in its business model also comes as federal regulators have started to crack down on the sale of compounded GLP-1s. The Department of Health and Human Services had referred Hims & Hers to the Justice Department for possible criminal violations, and last week, the Food and Drug Administration sent out warning letters to 30 telehealth companies<\/a> for the \u201cillegal\u201d marketing of compounded drugs.<\/p>\n","protected":false},"excerpt":{"rendered":"Telehealth company Hims & Hers on Monday announced a \u201cstrategic shift\u201d in its business model, partnering with pharmaceutical…\n","protected":false},"author":2,"featured_media":39289,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[621,1440,272],"class_list":{"0":"post-39288","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-hims","9":"tag-hims-hers","10":"tag-novo-nordisk"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116221382879803215","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/39288","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=39288"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/39288\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/39289"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=39288"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=39288"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=39288"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}